Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

2.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
3.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
4.

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease.

Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ.

Urology. 2005 Mar;65(3):616-21.

PMID:
15780403
5.

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1904-13. doi: 10.1158/1055-9965.EPI-08-1173.

6.

Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

Int J Urol. 2010 May;17(5):466-75. doi: 10.1111/j.1442-2042.2010.02502.x. Epub 2010 Mar 10.

7.

Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status.

Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW.

Urology. 2001 Sep;58(3):386-92.

PMID:
11549486
8.
9.

Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.

Cipolla BG, Ziade J, Bansard JY, Moulinoux JP, Staerman F, Quemener V, Lobel B, Guillé F.

Cancer. 1996 Sep 1;78(5):1055-65.

10.

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.

11.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
12.

The association between measures of progression and survival in castrate-metastatic prostate cancer.

Scher HI, Warren M, Heller G.

Clin Cancer Res. 2007 Mar 1;13(5):1488-92.

13.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G.

Lancet Oncol. 2009 Mar;10(3):233-9. doi: 10.1016/S1470-2045(08)70340-1. Epub 2009 Feb 11.

14.
15.

Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.

Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, Ma Y, Ward DC, Vogelzang NJ, Fink LM.

Am J Clin Pathol. 2010 Dec;134(6):964-9. doi: 10.1309/AJCPH92SXYLIKKTS.

PMID:
21088161
16.

Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2009 Mar;181(3):1091-7. doi: 10.1016/j.juro.2008.11.015. Epub 2009 Jan 16.

PMID:
19150091
17.

Prognostic factors in metastatic prostate cancer.

Yigitbasi O, Ozturk U, Goktug HN, Gucuk A, Bakirtas H.

Urol Oncol. 2011 Mar-Apr;29(2):162-5. doi: 10.1016/j.urolonc.2009.03.013. Epub 2009 May 17.

PMID:
19450995
18.

Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.

Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ.

J Urol. 2008 Jun;179(6):2187-91; discussion 2191. doi: 10.1016/j.juro.2008.01.102. Epub 2008 Apr 18.

PMID:
18423725
19.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

PMID:
21723797
20.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Amato RJ, Melnikova V, Zhang Y, Liu W, Saxena S, Shah PK, Jensen BT, Torres KE, Davis DW.

Urology. 2013 Jun;81(6):1303-7. doi: 10.1016/j.urology.2012.10.041. Epub 2013 Apr 23.

PMID:
23622774

Supplemental Content

Support Center